Related Experiment Video

Updated: May 30, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis

M Adnan Nadir1, Li Wei, Douglas H J Elder

  • 1Centre for Cardiovascular and Lung Biology, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom.

Journal of the American College of Cardiology
|July 30, 2011
PubMed

Insights

Renin-angiotensin system blockade therapy, including ACE inhibitors and ARBs, improves survival and reduces cardiovascular events in patients with aortic stenosis. This finding challenges previous contraindications for these medications in AS patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Informatics

Background:

  • Aortic stenosis (AS) traditionally contraindicates renin-angiotensin system (RAS) blockade.
  • RAS inhibitors may offer cardioprotective benefits and improve left ventricular remodeling in AS.

Purpose of the Study:

  • To investigate the impact of RAS blockade therapy on outcomes in patients with aortic stenosis.
  • To evaluate the association between ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and mortality/cardiovascular events in AS.

Main Methods:

  • Utilized a large Scottish healthcare database linking prescribing, morbidity, mortality, and echocardiography data (1993-2008).
  • Identified 2,117 patients diagnosed with AS.
  • Employed Cox regression and propensity score analysis to assess the effects of ACEIs/ARBs on all-cause mortality and cardiovascular events.

Main Results:

  • 33% of AS patients (n=699) received ACEI or ARB therapy.
  • Treatment with ACEIs/ARBs was associated with significantly lower all-cause mortality (aHR 0.76) and fewer cardiovascular events (aHR 0.77).
  • Propensity score analysis corroborated the observed outcome benefits.

Conclusions:

  • ACEI/ARB therapy is linked to improved survival in patients with aortic stenosis.
  • RAS blockade is associated with a reduced risk of cardiovascular events in the AS population.
  • Findings suggest a potential re-evaluation of contraindications for RAS inhibitors in AS management.
Abstract

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...